The biomarkers that are currently used for a clinical diagnosis, including carcinoembryonic antigen (CEA) and carbohydrate antigen (CA), are deficient in sensitivity and specificity, leading to an early gastric cancer diagnosis rate of lower than 15% [27, 28]. The gene discussed is CEACAM5; the disease is gastric cancer.